1361199-03-2

Upstream product

• 72167-80-7 3-bromo-7-methoxy-2H-chromen-2-one 
• 531-59-9 7-methoxycoumarin 
• 146900-52-9 3-bromo-7-hydroxy-2H-1-benzopyran-2-one 
• 1361198-91-5 3-bromo-7-((1-methylpiperidin-4-yl)oxy)-2H-chromen-2-one 
• 3900-89-8 2-Chlorobenzeneboronic acid 
• 93-35-6 7-hydroxy-2H-chromen-2-one 
• 106-52-5 N-methyl-4-hydroxypiperidine 

Relevant academic research and scientific papers

3-arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition

The potential therapeutic benefits associated with Hsp90 modulation for the treatment of cancer and neurodegenerative diseases highlight the importance of identifying novel Hsp90 scaffolds. KU-398, a novobiocin analogue, and silybin were recently identified as new Hsp90 inhibitors. Consequently, a library of 3-arylcoumarin derivatives that incorporated the structural features of KU-398 and silybin was designed, synthesized, and evaluated against two breast cancer cell lines. Western blot analysis confirmed that the resulting 3-arylcoumarin hybrids target the Hsp90 protein folding machinery.